Disease Severity Among Bio-Naive RA Patients on Csdmards

被引：0
|
作者：
Harrold, Leslie R. [1 ,2 ]
Griffith, Jenny [3 ]
Litman, Heather J. [2 ]
Feng, Hua [2 ]
Schlacher, Casey A. [3 ]
Kremer, Joel [4 ,5 ]
机构：
[1] Univ Massachusetts, Sch Med, Worcester, MA USA
[2] Corrona LLC, Waltham, MA USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Albany Med Coll, Albany, NY 12208 USA
[5] Ctr Rheumatol, Albany, NY USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
543
引用
收藏
页数：3
相关论文
共 50 条
  • [31] MINIMAL DISEASE ACTIVITY RESPONSE PATTERNS IN BIO-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH GUSELKUMAB: A MACHINE LEARNING ANALYSIS
    Zabotti, Alen
    Ohrndorf, Sarah
    Tillett, William
    Neuhold, Marlies
    van Speybroeck, Michel
    Theander, Elke
    Contre, Christine
    Sharaf, Mohamed
    Shawi, May
    Perate, Michelle
    Kollmeier, Alexa
    Richette, Pascal
    RHEUMATOLOGY, 2023, 62
  • [32] Onset of Response With Infliximab vs. Vedolizumab in the Treatment of Bio-Naive Inflammatory Bowel Disease
    Fourment, Chris
    Ritter, Timothy E.
    Kuten, Samantha A.
    Hardin, Thomas C.
    Van Anglen, Lucinda J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S389 - S390
  • [33] Tofacitinib versus Vedolizumab Among Bio-naive Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison
    Gros, B.
    Constantine-Cooke, N.
    Kennedy, J.
    Elford, A. T.
    O'Hare, C.
    Noble, C.
    Jones, G. R.
    Arnott, I. D.
    Plevris, N.
    Lees, C. W.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I102 - I103
  • [34] TOFACITINIB VERSUS VEDOLIZUMAB AMONG BIO-NAIVE PATIENTS WITH ULCERATIVE COLITIS: A REAL-WORLD PROPENSITY-WEIGHTED COMPARISON
    Gros, Beatriz
    Constantine-Cooke, Nathan
    Kennedy, Jake
    Elford, Alexander T.
    O'Hare, Claire
    Noble, Colin
    Jones, Gareth-Rhys
    Arnott, Ian
    Plevris, Nikolas
    Lees, Charlie W.
    GASTROENTEROLOGY, 2024, 166 (05) : S1426 - S1426
  • [35] Vedolizumab Outcomes in Real-world Bio-naive Ulcerative Colitis and Crohn's Disease Patients (EVOLVE) in North America
    Yarur, Andres
    Bassel, Marielle
    Stein, Dara
    Kim, Hankyul
    Radulescu, Gabriela
    Lopez, Claudia
    Lissoos, Trevor
    Demuth, Dirk
    Bressler, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S374 - S374
  • [36] Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn's disease patients (EVOLVE) in Canada: Interim results
    Bressler, B.
    Greenup, A. -J.
    Bassel, M.
    Stein, D.
    Soni, M.
    Radulescu, G.
    Neish, C.
    Khalid, J. M.
    Demuth, D.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S382 - S382
  • [37] Response to Adalimumab Therapy in bio-naive patients and in Infliximab nonresponders: Results of a Phase Illb Clinical Trial
    Lofberg, R.
    Louis, E.
    Reinisch, W.
    Kron, M.
    Camez, A.
    Pollack, P.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S27 - S28
  • [38] Real-world experience on the efficacy and safety of apremilast in bio-naive patients with moderate plaque psoriasis
    Conti, Andrea
    Tiberio, Rossana
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (11) : 1900 - 1900
  • [39] Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naive Patients with Crohn's Disease and Fistula Initiated on Ustekinumab
    Zhdanava, Maryia
    Kachroo, Sumesh
    Boonmak, Porpong
    Burbage, Sabree
    Shah, Aditi
    Lefebvre, Patrick
    Kerner, Caroline
    Pilon, Dominic
    ADVANCES IN THERAPY, 2024, 41 (10) : 3922 - 3933
  • [40] 5-Year Outcomes of Adalimumab Use in Nationwide Cohort of Bio-Naive Ulcerative Colitis Patients
    Sundararajan, Ramaswamy
    Patel, Manthankumar
    Trivedi, Chinmay
    Khan, Nabeel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S907 - S907
12345